Asthma diagnosis and treatmentThe Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial
Section snippets
Study population
Inclusion criteria for study subjects were individuals with asthma between 18 and 55 years of age with a baseline FEV1 55% to 85% predicted and a methacholine PC20 ≤12 mg/mL. Because FEV1 reversibility was an outcome variable, this was not used as an inclusion criterion. No ICS or systemic corticosteroids were allowed for at least 4 weeks before enrollment. No smoking was allowed for 1 year before enrollment, and cumulative exposure was less than 10 pack-years. Other exclusion criteria included
Study population
A total of 83 subjects were enrolled, with 36 men and 47 women. Thirty-eight minority (African American and Latino) individuals were enrolled. These subjects came from surrounding communities of the individual ACRN centers and not specifically from patients seen at these testing referral centers. Of the 83 enrolled subjects, 72 completed the initial 6-week trial. The reasons for dropout are described below. The baseline descriptive characteristics of the 72 subjects are shown in Table I.
Discussion
This ACRN protocol prospectively evaluated biomarkers and characteristics associated with ICS response and, in addition, determined whether a short-term response or lack of response to ICS predicted longer-term asthma control. With regard to biomarkers and characteristics as predictors of ICS response, only the response to a short-acting β2-agonist (albuterol), low percentage predicted FEV1, and FEV1/FVC ratio had a strong (r ≥± 0.6) correlation with response. Of potential importance was the
References (23)
Inflammation in asthma: the cornerstone of the disease and target of therapy
J Allergy Clin Immunol
(1998)- et al.
Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma
J Allergy Clin Immunol
(1987) - et al.
Significant variability in response to inhaled corticosteroids for persistent asthma
J Allergy Clin Immunol
(2002) - et al.
Measuring asthma control in group studies: do we need airway calibre and rescue beta2-agonist use?
Respir Med
(2001) - et al.
Non-eosinophilic corticosteroid unresponsive asthma
Lancet
(1999) - et al.
Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients
Chest
(2006) Sputum induction in asthma: a research technique or a clinical tool?
Chest
(2006)- et al.
Characterization of within-subject responses to fluticasone and montelukast in childhood asthma
J Allergy Clin Immunol
(2005) - et al.
Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids
J Allergy Clin Immunol
(2005) - et al.
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial
Lancet
(2002)
Time to onset of effect of fluticasone propionate in patients with asthma
J Allergy Clin Immunol
Cited by (155)
Baseline Characteristics and ICS/LAMA/LABA Response in Asthma: Analyses From the CAPTAIN Study
2024, Journal of Allergy and Clinical Immunology: In PracticeAdding oscillometry to spirometry in guidelines better identifies uncontrolled asthma, future exacerbations, and potential targeted therapy
2024, Annals of Allergy, Asthma and ImmunologyThe ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review
2023, Journal of Allergy and Clinical Immunology: In PracticeAssociation of the gut microbiome and metabolome with wheeze frequency in childhood asthma
2022, Journal of Allergy and Clinical ImmunologyLipid-mediated innate lymphoid cell recruitment and activation in aspirin-exacerbated respiratory disease
2021, Annals of Allergy, Asthma and ImmunologyPredictive factors of response to inhaled corticosteroids in newly diagnosed asthma: A real-world observational study
2020, Annals of Allergy, Asthma and Immunology
Supported by US National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI)-HL04285, HL051810, HL051823, HL051831, HL051834, HL051843, HL051845, and HL056443.
Disclosure of potential conflict of interest: R. J. Martin has consulting arrangements with Ivax, Merck, GlaxoSmithKline, Schering, Novartis, Genentech, Altana, and Sanofi-Aventis; has received grant support from GlaxoSmithKline and Altana; and is on the speakers' bureau for Ivax, Merck, Novartis, and Genentech. S. J. Szefler has consulting arrangements with AstraZeneca, GlaxoSmithKline, Aventis, Genentech, and Merck and has received grant support from the NIH, the NHLBI, the National Institute of Allergy and Infectious Diseases (NIAID), and Ross Pharmaceuticals. M. Kraft has consulting arrangements with Genentech, GlaxoSmithKline, Merck, Boehringer Ingelheim, Asthmatx, and TEVA; has received grant support from GlaxoSmithKline, Genentech, Altana, and Asthmatx; and is on the speakers' bureau for GlaxoSmithKline, Genentech, Merck, Schering, Sepraco, and Pfizer. H. A. Boushey has consulting arrangements with Watermark Research Protein Design Lab, Altana, and Sumitomo; has received grant support from GlaxoSmithKline; and has received honoraria from Merck, Novartis, Sanofi-Aventis, and Genentech. V. M. Chinchilli has received grant support from the Asthma Clinical Research Network, the NIH, and the Childhood Asthma Research and Education Network. T. J. Craig has consulting arrangements with Alcon, Johnson and Johnson, and TEVA; has received grant support from GlaxoSmithKline, Merck, Sanofi-Aventis, Boehringer Ingelheim, Dyax, ZLB, LEV, Pharming, and AstraZeneca; and is on the speakers' bureau for Merck, Pfizer, AstraZeneca, Boehringer Ingelheim, Dyax, ZLB, LEV, Pharming, and Sanofi-Aventis. E. A. DiMango has consulting arrangements with AstraZeneca and has received grant support from Novartis and Genentech. A. Deykin has consulting arrangements with Aerocrine; owns stock in Biogen Idec; is employed by Biogen Idec; has received grant support from Merck; and is on the speakers' bureau for Merck. J. V. Fahy has consulting arrangements with Arriva Pharmaceuticals, Abgenix, Oxagen, and Zymogenetics and has received grant support from the NHLBI, the California Tobacco Research Program, and the University of California, San Francisco Sandler Asthma Program. E. Israel has consulting arrangements with Asthmatx, Critical Therapeutics, Genentech, Merck, Novartis, Protein Design Lab, Schering Plough, and Wyeth Research; has received grant support from Asthmatx, Boehringer Ingelheim, Centocor, Genentech, GlaxoSmithKline, and Merck; and is on the speakers' bureau for Genentech and Merck. R. F. Lemanske, Jr, has consulting arrangements with Merck, GlaxoSmithKline, AstraZeneca, Aventis, and Novartis; has pending US patent application serial number 11/176026, published as US 2006-0069074 on March 30, 2006; has received grant support from the NHLBI and the NIAID; and is on the speakers' bureau for Merck, GlaxoSmithKline, AstraZeneca, and Aventis. F. T. Leone has received grant support from the NIH, the American Lung Association, the Pennsylvania Department of Health, and the Philadelphia Department of Health and is on the speakers' bureau for Pfizer. S. P. Peters has consulting arrangements with the NIH, Adelphi, the American Thoracic Society, AstraZeneca, Discovery, Ception Therapeutics, Genentech, Novartis, Omnicare, the Rad Foundation, Respiratory Medicine, Respiratory Research, and Sanofi-Aventis; has received grant support from the NIH, the NHLBI, the American Lung Association, Abaris, AstraZeneca, Altana, Boehringer Ingelheim, Centocor, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Wyeth; and has participated in physician education programs that included speakers' bureau and Continuing Medical Education programs for the American College of Chest Physicians, the American Thoracic Society, the American Academy of Allergy, Asthma, & Immunology, the American College of Allergy, Asthma and Immunology, AstraZeneca, Merck, Genentech, Novartis, Practicome, Pri-Med, Respiratory and Allergic Disease, and UpToDate. C. A. Sorkness has consulting arrangements with AstraZeneca and GlaxoSmithKline; has received grant support from GlaxoSmithKline; and is on the speakers' bureau for GlaxoSmithKline. M. E. Wechsler has consulting arrangements with Merck, Genentech, Novartis, and Pfizer and is on the speakers' bureau for Merck, GlaxoSmithKline, and Novartis. The rest of the authors have declared that they have no conflict of interest.